PubRank

Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors

Clinical Trial ID NCT01968109

PubWeight™ 64.69‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01968109

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 2015 5.10
2 Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol 2015 2.74
3 Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov 2015 2.25
4 PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci Transl Med 2016 2.16
5 The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol 2016 2.09
6 The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Clin Ther 2015 1.73
7 Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol 2015 1.54
8 Immunotherapy in the treatment of non-small cell lung cancer. Lung Cancer 2014 1.35
9 Intratumoral immunization: a new paradigm for cancer therapy. Clin Cancer Res 2014 1.24
10 Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy. Oncoimmunology 2014 1.22
11 Nivolumab in NSCLC: latest evidence and clinical potential. Ther Adv Med Oncol 2015 1.21
12 Immune modulation for cancer therapy. Br J Cancer 2014 1.15
13 Immunology and Immunotherapy of Head and Neck Cancer. J Clin Oncol 2015 1.10
14 Nivolumab in melanoma: latest evidence and clinical potential. Ther Adv Med Oncol 2015 1.09
15 Immunological landscape and immunotherapy of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2015 1.06
16 Inhibitory Receptors Beyond T Cell Exhaustion. Front Immunol 2015 1.05
17 Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade. Clin Cancer Res 2015 1.04
18 Pembrolizumab. J Immunother Cancer 2015 0.99
19 Immune checkpoint inhibitors in clinical trials. Chin J Cancer 2014 0.98
20 Cancer immunotherapy in clinical practice -- the past, present, and future. Chin J Cancer 2014 0.98
21 PD-1/PD-L1 blockade in cancer treatment: perspectives and issues. Int J Clin Oncol 2016 0.95
22 Advances in immunotherapy for treatment of lung cancer. Cancer Biol Med 2015 0.95
23 The emerging role of immunotherapy in head and neck squamous cell carcinoma (HNSCC): anti-tumor immunity and clinical applications. Ann Transl Med 2016 0.93
24 Therapeutic vaccines in HBV: lessons from HCV. Med Microbiol Immunol 2015 0.93
25 Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander". Toxins (Basel) 2014 0.92
26 Updates in Therapy for Advanced Melanoma. Cancers (Basel) 2016 0.91
27 Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers. Hum Vaccin Immunother 2016 0.89
28 Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma. Ther Adv Urol 2015 0.88
29 Immunotherapy for cancer in the central nervous system: Current and future directions. Oncoimmunology 2015 0.88
30 Non-Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy. J Thorac Oncol 2015 0.87
31 CD4+ T Cells Expressing PD-1, TIGIT and LAG-3 Contribute to HIV Persistence during ART. PLoS Pathog 2016 0.87
32 Immune checkpoint inhibitors: therapeutic advances in melanoma. Ann Transl Med 2015 0.87
33 Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overview. Urol Oncol 2016 0.86
34 Lymphocyte Activation Gene 3 (LAG-3) modulates the ability of CD4 T-cells to be suppressed in vivo. PLoS One 2014 0.86
35 PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence. Onco Targets Ther 2014 0.85
36 The tumor microenvironment in esophageal cancer. Oncogene 2016 0.83
37 Immune checkpoints and immunotherapy for colorectal cancer. Gastroenterol Rep (Oxf) 2015 0.83
38 Advances in immunotherapy for melanoma. BMC Med 2016 0.83
39 Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosis. BMC Med 2016 0.83
40 Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1. Immunotherapy 2015 0.81
41 Lymphocyte activation gene-3 (LAG-3, CD223) in plasmacytoid dendritic cells (pDCs): a molecular target for the restoration of active antitumor immunity. Oncoimmunology 2014 0.81
42 Advances in targeted and immunobased therapies for colorectal cancer in the genomic era. Onco Targets Ther 2016 0.81
43 Clinical utility of nivolumab in the treatment of advanced melanoma. Ther Clin Risk Manag 2016 0.81
44 The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment. Oncologist 2015 0.81
45 Reflections on immune checkpoint inhibition in non-small cell lung cancer. Transl Lung Cancer Res 2014 0.81
46 Targeting CD8+ T-cell tolerance for cancer immunotherapy. Immunotherapy 2014 0.81
47 Progression of benign prostatic hyperplasia is associated with pro-inflammatory mediators and chronic activation of prostate-infiltrating lymphocytes. Oncotarget 2016 0.81
48 PD-1 and PD-L1 antibodies for melanoma. Hum Vaccin Immunother 2014 0.80
49 Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors. Cancer Biol Med 2015 0.80
50 Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine. Gynecol Oncol 2016 0.79
51 Cancer stem cells and immunoresistance: clinical implications and solutions. Transl Lung Cancer Res 2015 0.79
52 Recent Advances in Immunotherapy in Metastatic NSCLC. Front Oncol 2016 0.79
53 Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced non-small cell lung cancer. Transl Lung Cancer Res 2014 0.78
54 Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect. J Immunol Res 2015 0.78
55 New clinical advances in immunotherapy for the treatment of solid tumours. Immunology 2015 0.76
56 Harnessing the PD-1 pathway in renal cell carcinoma: current evidence and future directions. BioDrugs 2014 0.76
57 An update on current management of advanced renal cell cancer, biomarkers, and future directions. Ann Cancer Res 2015 0.76
58 Lymphocyte-activation gene-3, an important immune checkpoint in cancer. Cancer Sci 2016 0.76
59 Melanoma immunotherapy. Cancer Biol Ther 2014 0.76
60 Lymphocyte activation gene 3 and coronary artery disease. JCI Insight 2016 0.75
61 Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment. Onco Targets Ther 2016 0.75
62 Adding fuel to the fire: immunogenic intensification. Hum Vaccin Immunother 2014 0.75
63 Immune checkpoint and inflammation as therapeutic targets in pancreatic carcinoma. World J Gastroenterol 2016 0.75
64 The controversial role of TNF in melanoma. Oncoimmunology 2015 0.75
Next 100